Mr. Lin owns an EMBA Degree from China Europe International Business School (CEIBS), a Master Degree in Finance from Lancaster University and a Bachelor Degree in Economics from Renmin University of China. Before founding DNV Capital, Mr. Lin was the partner of CDF Capital. Previously, he served in CDH investments and was responsible for the VC business in South China. While working for ZTE investment department, he was in charge of multiple investment projects in Asia, Africa and North America. Mr. Lin has 20 years of rich experience in financial and strategic investment areas. He has led investment in a series of projects in the Healthcare, Innovative Technology and TMT, including Poly Pharm （300630.SZ） , Vessix Vascular Inc., Venus Medtech (2500.HK), Broncus(2216.HK), Sorrento (SRNE. NASDAQ), Geneseeq, CANbridgepharma(1228.HK), Yingliu Electromechanical (603308.SH) , Bethel Auto Safety (603596.SH) and APT Electronics（836789.SZ).

投资代表项目

Mr. Wang has more than 20 years of experience in venture capital, private equity and TMT operations. Prior to joining DNV Capital, Mr. Wang worked at Morgan Creek Capital as Managing Director to manage PE/VC funds and co-investment programs in Asia. He started his investment career in CDH Investments and subsequently joined KPCB China. Prior to investing, Mr. Wang was a senior manager at PayPal, overseeing China products and Principal PM at Oracle’s Server Technology group. Mr. Wang holds an M.B.A. from Stanford Business School, a M.S. from College of William and Mary, and a B.S. from Randolph-Macon College.

投资代表项目

Mr. Yang has experience of more than 15 years in financial area and is especially experienced in equity investments, M&A and market value management and has established extensive network. Before founding TiD Investments, Mr. Yang served in RICHLINK Capital，China Galaxy Securities and Nanshan Group, where he had initiated several equity funds with total investments of over 3 billion RMB. Mr. Yang holds a Master in Economics from Huazhong University of Science and Technology.

投资代表项目

Ms. Lily Shi holds an EMBA degree from Tsinghua University. She completed her undergraduate studies at Beijing Normal University and furthered her postgraduate education at Peking University HSBC Business School. This diverse educational background has laid a solid foundation for her career in investment.

Prior to joining DNV Capital, Ms. Shi served as a partner at Yifeng Capital, where she focused on global biopharmaceutical venture capital and private equity investments. She has been involved in numerous investments in high-quality enterprises both in China and abroad, including companies such as Shenzhen Chipscreen Biosciences, Frontier Biotech, Shenzhen Prometheus, Ascentage Pharma, Harbour BioMed, Quanxin Biotech, Huahao Tianyuan, Apexigen, and Centrexion Therapeutics, covering a variety of innovative drug categories. In recognition of her outstanding investment performance and research capabilities, she has been honored with awards such as the "Zero2IPO・Top 30 Investment Institutions in China's Healthcare Sector" and the "CVRanking・Top 10 Best Biopharmaceutical Investment Institutions." She has also been interviewed by the world-renowned scientific journal Nature.

Ms. Joyce Lv specializes in technology in advanced material, innovative medical device and AI. She has led and deeply involved in several investments in these areas. Ms.Lv used to work in Argus & Advisory and Roland Berger Strategy Consultancy. In 2013, she joined McKinsey & Company and participated in several large MNC strategy formulations and enterprise reforms globally. She has both deep understanding in material tech and rich experience in enterprise strategic management. Ms. Lv Zhou owns a Bachelor degree in Chemistry from Peking University, Masters in Finance and Master in Mathematics from Columbia University, and an EMBA Degree from Tsinghua University.

投资代表项目

Investment Department James Ding

Investment Department Eric He

Finance Department Yiya Zhang

Investor Relations Emma Miao

Investor Relations Sharon Zhu